Teva Parenteral Medicines recently announced that it will issue a voluntary recall order for six lots of the company's generic cancer drug called Adrucil.
Teva Parenteral Medicines which is a division of Teva Pharmaceutical Industries Limited said that the recall order was made due to a possible presence of a matter recognized as "aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals."
The company released a statement claiming that no reports were received due the adverse effects related to the recall. It added that intravenous administration of the affected produces will have adverse effects ranging from inflammation, allergic reactions as well as blockage of blood vessels which could lead to tissue death and may present life-threatening effects.
The six lots included in the recalled are numbers 31318138B, 31318136B, 31317957B, 31317920B, 31317859B and 31317857B. The 31317857B lot is expected to expire in August while the remaining five will expire in December.
Adrucil, the recalled product, is used to treat patients suffering from various forms of cancer including breast, colon, pancreas, rectum and stomach, according to Philadelphia Business Journal. Teva has already sent out an Urgent Drug Recall Letter to all its direct customers notifying them of the recall.
The company also advised its consumers to immediately contact their physician if they experience any adverse effect related to the intake of their products. Teva said that the company has already notified the United States Food and Drug Administration about the recall, according to Business Wire.
Prior to the recent recall, Teva abandoned its plans to acquire Mylan NV. The company instead came into a $40.5 billion deal to acquire the generic business of Allergan.